Newron Pharmaceuticals – EKF interview

Newron Pharmaceuticals – EKF interview

Newron Pharmaceuticals — 4 videos in collection

More on this equity

Newron Pharmaceuticals is focused on the development of its novel schizophrenia drug with two pivotal Phase III trials due to start in Q221. The company already has a marketed product for Parkinson’s disease, Xadago, sold in Europe and the US. A further Xadago trial for the treatment of Parkinson’s dyskinesia could add to US sales and may start in 2021.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.